Bicara Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Bicara Therapeutics Reports 2024 Financial Results, Highlights Clinical Progress of Ficerafusp Alfa
Bicara Therapeutics' 2024 10-K filing highlights the company's ongoing clinical development of ficerafusp alfa, its lead bifunctional antibody, and its financial position.